reports
Simulations Plus to Participate in the BTIG Digital Health Forum
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O’Connor will join a panel discussion entitled “Supporting Drug Development, Clinical Trials, and Biopharma” at 2:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings through...
Simulations Plus and the University of Connecticut Receive New FDA Gra...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmac...
Simulations Plus to Participate in the Stephens Annual Investment Conf...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings with investors throughout the day. The live audio webcast of Mr. O’Connor’s...
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vit...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion (ASD) formulations in different conditions and predict the impact of food and pH-dependent drug-drug interactions (DDIs) th...
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Resu...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $9.9 million, representing 53% of total revenue Services revenue increased 39% to $8.8 million, re...
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earning...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this ...
Simulations Plus and the University of Southern California Secure NIH ...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate wi...
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Glob...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024. Mr. O’Connor will host one-on-one and small group meetings throughout the day. This event is expected to include more than 200 companies as well ...
Simulations Plus Optimizes Business Unit Structure to Support Future G...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future growth following the Company’s recent acquisitions. These actions will be effective August 30, 2024. “Over the past year, we made two key acquisitions, including the largest in our corporate history,” said Shawn O’Connor, Chief Executive Officer. “As a r...
Simulations Plus Releases DILIsym® X
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, has released the latest version of its flagship quantitative systems toxicology (QST) platform, version X. “Modeling and predictions regarding drug efficacy are critical in the drug development process—but so are predictions regarding safety,” said , President of Quantitative Systems Pharmacology (QSP) Solutions at Simulations Plus. “We know there is often a gap between ...
Simulations Plus Releases ADMET Predictor® Version 12
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of version 12.0 of (AP12), its flagship machine learning (ML) modeling platform for the discovery, design, and optimization of new molecules. AP12 includes: Enhanced Models: New and expanded models offer greater predictive accuracy, with an average 30% increase in training set sizes, for microsome and hepatocyte clearance, protein binding, ...
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Le...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will attend KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on Monday, August 5, 2024, in Vail, Colorado. In addition to hosting one-on-one meetings throughout the day, Mr. O’Connor will join a panel discussion entitled “AI and Digital Solutions for Drug Discovery” followed...
Simulations Plus Announces New Research Project with the International...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded research project with the International Collaboration on Cosmetics Safety (ICCS) to evaluate the use of physiologically-based kinetic (PBK) modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients. In a competitive bidding process, Simulations Plus was selected for its proposal to establish wo...
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increased 18% to $6.6 million, repre...
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life ...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit on Wednesday, June 26, 2024, at Morgan Stanley’s headquarters in New York City. Mr. O’Connor will join a panel discussion entitled “Transforming Research – Optimizing from Lab to Trial” at 2:10 p.m. EDT, and he will h...
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this link to re...
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platfor...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries (“Pro-ficiency”), a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development. Simulations Plus acquired Pro-ficiency from QHP Capital, L.P. (management company for NovaQuest Private Equity) (“QHP Capital”) and Pro-ficiency’s minority shareholders...
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutio...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN. Mr. O’Connor will host one-on-one and small group meetings throughout the day. Each year, Craig-Hallum hosts a multi-industry investor conference featuring more than 130 publ...
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the release of . Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streaml...
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that the U.S. FDA has renewed its licenses to the software platform. DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI). The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions. DILIsym predict...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.